Literature DB >> 2155526

Ki-1-positive non-Hodgkin's lymphomas. An immunophenotypic, ultrastructural, and morphometric study.

B F Burns1, I Dardick.   

Abstract

The authors studied four cases of diffuse, large cell non-Hodgkin's lymphomas with strong Ki-1 expression to determine if they shared characteristic ultrastructural or morphometric features in common. The tumor cells in these lymphomas all had very abundant cytoplasm, which often showed a concentration of organelles, especially mitochondria and Golgi apparatus, in regions next to nuclear concavities. One case had very complex cytoplasmic membrane projections resembling a "microvillous" lymphoma. These ultrastructural features combined with the frequent reniform nuclei and scattered lysosomes suggested histiocyte differentiation. However the immunophenotype was variable, more often showing "activation" markers and abnormal T-cell marker patterns. The mean nuclear area for all cases was between 38.3 +/- 12.7 to 42.3 +/- 16.2 microns2, roughly twice the size of the small lymphocyte population. The nuclear contour index, a measure of irregularity of the nuclear membrane, ranged from 4.75 +/- 0.86 to 6.36 +/- 1.89 (a circle is 3.54). These nuclear parameters are comparable in size to those of previously measured large cell lymphomas but exhibit more nuclear irregularity than most. Ki-1 lymphomas appear to represent a somewhat diverse group of tumors of lymphoid origin that exhibit some hybrid features of histiocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155526     DOI: 10.1093/ajcp/93.3.327

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

Review 1.  Case report: primary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum.

Authors:  I Yoshikawa; I Murata; Y Tanaka; K Kanagawa; A Tabaru; H Itoh; M Otsuki
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 2.  Primary central nervous system lymphomas--an update.

Authors:  K A Jellinger; W Paulus
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.